Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Non-Current Assets (2016 - 2025)

Amicus Therapeutics' Other Non-Current Assets history spans 16 years, with the latest figure at $13.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 0.72% year-over-year to $13.7 million, compared with a TTM value of $13.7 million through Dec 2025, up 0.72%, and an annual FY2025 reading of $13.7 million, up 0.72% over the prior year.
  • Other Non-Current Assets for Q4 2025 was $13.7 million at Amicus Therapeutics, up from $12.9 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $25.2 million in Q1 2022, with the low at $12.9 million in Q3 2025.
  • Average Other Non-Current Assets over 5 years is $18.4 million, with a median of $18.6 million recorded in 2023.
  • Year-over-year, Other Non-Current Assets increased 27.92% in 2021 and then plummeted 30.95% in 2025.
  • Tracing FOLD's Other Non-Current Assets over 5 years: stood at $24.4 million in 2021, then fell by 21.23% to $19.2 million in 2022, then fell by 3.58% to $18.6 million in 2023, then decreased by 26.48% to $13.6 million in 2024, then grew by 0.72% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Other Non-Current Assets are $13.7 million (Q4 2025), $12.9 million (Q3 2025), and $13.4 million (Q2 2025).